Management of Borderline Resectable Pancreatic Cancer

Department of Surgery, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. <>
Surgical Oncology Clinics of North America (Impact Factor: 1.81). 04/2010; 19(2):359-70. DOI: 10.1016/j.soc.2009.11.006
Source: PubMed


Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C). These patients are particularly well suited to a surgery-last strategy with induction therapy consisting of chemotherapy (gemcitabine alone or in combination) followed by chemoradiation. With appropriate selection and preoperative planning, many patients with borderline resectable disease derive clinical benefit from multimodality therapy. The use of a standardized system for the staging of localized pancreatic cancer avoids indecision and allows for the optimal treatment of all patients guided by the extent of their disease. In this article, 2 case reports are presented, and the term borderline resectable pancreatic cancer is discussed. The advantages of neoadjuvant therapy and surgery are also discussed.

1 Follower
4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of: Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10), 1073-1081 (2010). Over the last decade, adjuvant therapy in the treatment of resected pancreas adenocarcinoma has had its value established. Such treatment incrementally increases 5-year survivorship and delays time to tumor recurrence. The backbone of adjuvant therapy is the single-agent gemcitabine, based primarily on results from the Charité Onkologie Clinical (CONKO)-001 study. Based on the combined results of the European Study Group for Pancreas Cancer (ESPAC)-1 and ESPAC-3 trials, Neoptolemos and colleagues have established both bolus 5-fluorouracil and leucovorin and gemcitabine as standard options for resected pancreatic cancer. Gemcitabine remains the main standard therapy based on its ease of administration and a more favorable toxicity profile; however, there is now a clearly validated alternate option of 5-fluororuacil and leucovorin based on the results of ESPAC-3. Moving forward, the integration of novel cytotoxic and targeted agents into adjuvant therapy, along with refining the role of neoadjuvant therapy for patients with resectable pancreas cancer, will hopefully accrue a more substantial improvement in outcome for patients with resected pancreas adenocarcinoma.
    No preview · Article · Feb 2011 · Expert Review of Anti-infective Therapy
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although a variety of imaging techniques, such as multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic ultrasound, and fluorodeoxyglucose positron emission tomography have all been used in the initial diagnostic assessment of pancreatic lesions, in general, MDCT is the mainstay of diagnosis. This is due in large part to the high spatial resolution of its three-dimensional data sets that are indispensable in determining the local extent of tumor infiltration. This article describes MRI and MDCT techniques and accuracy and new horizons in MDCT in imaging of pancreatic cancer.
    No preview · Article · Mar 2012 · Gastroenterology clinics of North America
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: El cáncer de páncreas es una enfermedad de mal pronóstico; la tasa de supervivencia de los pacientes a cinco años es de 5%-15% luego del tratamiento radical. Su evolución silenciosa pero agresiva, asociada a la sintomatología inespecífica, retarda el diagnóstico, razón por la cual solo entre 15% y 20% de las lesiones se pueden resecar en el momento del diagnóstico; ello no es posible en el caso de las restantes, bien sea por cáncer localmente avanzado (30%) o por metástasis (50%); por lo tanto, se requiere otro enfoque terapéutico para mejorar la calidad de vida de estos pacientes y si es posible prolongarles la supervivencia. La quimioterapia y la radioterapia como tratamientos únicos o en combinación no han logrado resultados satisfactorios. La investigación continúa con el fin de hallar el protocolo con el que se logre mejorar la calidad de vida y un aumento significativo en la supervivencia.
    Full-text · Article · Apr 2012 · Iatreia
Show more